Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Eli Lilly director Ralph Alvarez acquired 15 shares of common stock through a deferral plan, as reported in a recent SEC filing.

Summary

• Ralph Alvarez, a director at Eli Lilly & Co, acquired 15 shares of common stock on March 18, 2024.
• The shares were acquired at a price of $762.66 per share.
• This transaction was part of the Lilly Directors' Deferral Plan, where the shares are deferred in lieu of cash compensation.
• The shares will be settled in common stock after Mr. Alvarez's separation from service.
• Following this transaction, Mr. Alvarez beneficially owns 54,013 shares of Eli Lilly common stock.

Sentiment

Score: 7

Explanation: The transaction is a routine director share acquisition through a deferral plan, indicating a neutral to slightly positive sentiment due to the director's continued investment in the company.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

Director share acquisitions are a common occurrence in publicly traded companies and are often seen as a sign of confidence in the company's future performance.

Comparison to Industry Standards

• Director share acquisitions are a standard practice across publicly listed companies.
• The use of deferral plans for director compensation is also a common practice.
• The specific details of the plan and the number of shares acquired are specific to Eli Lilly and its compensation policies.

Stakeholder Impact

• The share acquisition by a director may be viewed positively by shareholders as a sign of confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, SEC Form 4, LLY, Ralph Alvarez, Stock Units